SCHEDULE 13D/A: Dr. Lawrence Blatt's Stake in Aligos Therapeutics Drops Below 5% Threshold
Beneficial Ownership Update
Dr. Lawrence M. Blatt has filed an amended Schedule 13D, indicating his beneficial ownership in Aligos Therapeutics, Inc. has fallen below the 5% reporting threshold.
Summary
- Dr. Lawrence M. Blatt's beneficial ownership in Aligos Therapeutics, Inc. (Issuer) has decreased to 175,509 shares of Common Stock.
- This represents 3.2% of the Issuer's outstanding Common Stock, based on 5,314,311 shares outstanding as of March 6, 2025.
- The filing, Amendment No. 1 to Schedule 13D, reports that Dr. Blatt ceased to be the beneficial owner of more than five percent of the outstanding shares as of March 10, 2025.
- His beneficial ownership includes shares held directly, through the Lawrence M. Blatt Living Trust, PENSCO Trust Company LLC Custodian FBO Dr. Lawrence Blatt IRA, Zachary David Blatt Irrevocable Trust, Zoe Anne Blatt Irrevocable Trust, shares underlying Common Warrants, and shares underlying options vesting within 60 days.
- The reported amounts reflect a 1-for-25 reverse stock split effected by the Issuer on August 19, 2024.
- No transactions with respect to the Common Stock were effected by the Reporting Person during the past 60 days.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing reporting a change in beneficial ownership below a threshold. It contains no positive or negative commentary on the company's performance or outlook, thus maintaining a neutral sentiment.
Future Outlook
The document does not contain any forward-looking statements or guidance.
Industry Context
This filing is a standard regulatory disclosure regarding a change in a significant shareholder's ownership stake, which is common in the biotech/pharmaceutical industry as companies evolve and early investors or founders adjust their positions. It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: The reduction of a significant individual's stake below the 5% threshold may be noted by investors, but the document does not provide reasons for the change, limiting its immediate impact on sentiment.
Key Dates
| Date | Description |
|---|---|
| 2023-11-06 | Original Schedule 13D filed with the SEC. |
| 2024-08-19 | 1-for-25 reverse stock split of the Issuer's securities effected. |
| 2025-03-06 | Date as of which 5,314,311 shares of Common Stock were outstanding, as disclosed in the Issuer's Annual Report on Form 10-K. |
| 2025-03-10 | Date of event which required the filing of this statement (Dr. Blatt ceased to be a 5% beneficial owner). |
| 2025-03-12 | Date of signature for Amendment No. 1 to Schedule 13D. |
Keywords
Aligos Therapeutics, Lawrence M. Blatt, Schedule 13D, Beneficial Ownership, Common Stock, Shareholder Disclosure, Reverse Stock Split
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.